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Background: Jet nebulizers are commonly used to administer aerosolized tobramycin to CF patients. The aim of this study was to assess the
performance of disposable jet nebulizers as an alternative to reusable nebulizers such as the Pari LC Plus.
Method: From a survey conducted in 49 CF centers in France, 18 disposable jet nebulizer systems were selected. An in vitro study was performed with
20 jet nebulizer/air source combinations (18 disposable and 2 reusable) to determine their performance with tobramycin solution (300 mg/5 mL). A
scintigraphic deposition study in baboons was performed to validate the in vitro data.
Results: In vitro and in vivo results correlated. There was no overall relationship between the compressed air source and nebulizer performance,
but the nebulizer interface was responsible for significantly different results.
Conclusions: None of the disposable nebulizers tested in this study can be recommended as an alternative to the Pari LC Plus nebulizer for tobramycin.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Tobramycin; Nebulizer; Aerosol1. Background
Tobramycin is an aminoglycoside antibiotic commonly used
to treat Pseudomonas aeruginosa bronchial colonization in cystic
fibrosis (CF) patients. Aerosol delivery allows the respiratory tract
to be targeted and limits the side effects associated with systemic
treatment [1]. The efficacy of aerosolized antibiotics correlates
with the amount ofmedication deposited in the patient's lungs [2].
The amount of medication deposited in the lungs depends on
three main parameters, namely airway anatomy, patient ventilation
and aerosol characteristics [3]. Airway anatomy and ventilation⁎ Corresponding author. Aerodrug, Bat M, Faculté de Médecine, 10 Bld
Tonnellé, 37032 Tours cedex, France. Tel.: +33 2 47 36 60 61; fax: +33 2 47 36
61 96.
E-mail address: vecellio@med.univ-tours.fr (L. Vecellio).
1 On behalf of the GRAM (cystic fibrosis aerosols group).
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.10.004depend on the patient and the practitioner has little control over
them. The choice of nebulizer is therefore the only way the
practitioner can optimize aerosol delivery. There are many
nebulizers available on the market with significant differences in
terms of performance. Following recommendations made by
Novartis and in the European Cystic Fibrosis Society's consensus
document, the nebulizer currently recommended for administering
tobramycin aerosols to CF patients is the Pari LC+ jet nebulizer
with a suitable compressor operating at a flow rate of 4-6 l/min [4,5]
because it is the only nebulizer used in the pivotal trials for
determining safety and efficacy [5]. The Pari LC+ nebulizer is a
reusable nebulizer which requires around 15 min of inhalation to
deliver tobramycin into the lungs [6]. Like all reusable jet
nebulizers, it needs to be washed, disinfected, assembled and
prepared, which can be time-consuming for patients requiring daily
and often lifelong treatment. The use of mesh nebulizers reduces
nebulization time [7], but does not solve the problem of time-d by Elsevier B.V. All rights reserved.
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use disposable jet nebulizers which avoid the risk of bacterial
contamination [8] and do not require preparation and cleaning.
There is already widespread use of disposable nebulizers for
tobramycin in France thanks to financial support by the medical
agency. However, the performance of single-use devices has not
yet been studied in detail. As recommended in the European Cystic
Fibrosis Society's consensus document [4], new nebulizers should
be tested in vivo to demonstrate clinical equivalence before being
used by CF patients. The aim of this study was to measure the
performance of disposable nebulizers in order to test their potential
to be used in a comparative clinical study. For this purpose, the
GRAM (Aerosol Group of the French CF Society) carried out a
survey of the real-life use of disposable nebulizers for tobramycin
and compressors in 49 CF centers in France. The in vitro study
focused on comparing the fine particle mass and took into account
aerosol leakage, i.e. the mass of aerosol produced during the
exhalation phase, which differs widely from one device to another.
The results of this in vitro study were then validated in vivo by a
deposition study in baboons [3,9].
2. Materials and methods
2.1. Nebulizer systems used in French CF centers
2.1.1. Disposable nebulizer systems
A survey of the nebulizer systems prescribed for either home or
hospital care was carried out in 49 CF centers in France, using an e-
mail questionnaire. A nebulizer system is defined as the association
of a nebulizer reservoir, a compressor and an interface device (i.e.,
face mask, mouthpiece and tubes including valves) [2].
From this survey, 18 disposable nebulizer systems were
identified, corresponding to nine different nebulizer reservoirs
(Table 1). For example, the two Misty Neb nebulizer systems,
MistyNeb 2050G andMistyNeb 2035G, have the sameMistyNeb
nebulizer reservoir but different interfaces (T piece andmouthpiece
for Misty Neb 2035G; T-piece, Y piece, tube, mouthpiece, filter
and valves for the Misty Neb 2050G) (Fig. 1).
A “one-day” jet nebulizer (Atomisor NLU) was also selected
from the survey. It differs from the other disposable nebulizer
systems considered as single-use devices in that it can be used
several times during a single day.
2.1.2. Reusable nebulizer systems
Two reusable nebulizers recommended by the GRAM for both
home use and care in CF centers were selected for the study. They
were the Pari LC Plus nebulizer (Pari, Stanberg, Germany)
associated with a Turboboy® compressor SX (Pari, Stanberg,
Germany), and the Pari LC Sprint nebulizer (Pari, Stanberg,
Germany) associated with a Turboboy® compressor SX.
2.2. In vitro measurement
2.2.1. Drug solution
The tested dose was 300 mg/5 ml of tobramycin (TOBI®,
product No. 365723.2, Novartis, Rueil-Malmaison, France).2.2.2. Pressure measurement
An analogue gauge (Aschcroft pressure gauge 100T5500,
USA) was placed between the air source (compressor or wall
air) and the nebulizer in order to measure the nebulizer
operation pressure and to assess the influence of the operating
pressure on the performance of the nebulizer systems.
2.2.3. Inhaled mass
The inhaled mass of tobramycin was measured using a
respiratory pump (Harvard Apparatus, Ealing, UK) and by
collecting the aerosol on a filter. The nebulizer was connected to
its associated air source. An absolute filter (Pari Filter, Pulmomed,
Nanterre, France) was positioned between the nebulizer and the
respiratory pump operating at 15 breaths/min, 500 ml as inhalation
volume and an inhalation/exhalation ratio (I/E) of 1:1 in accordance
with the European Standard EN 13544-16 (CEN methodology).
The total nebulization time, defined as the time elapsed between the
beginning of nebulization and 1 min after the beginning of
spluttering, was recorded. The tobramycin inhalable mass
deposited on the filter was measured using the residual gravimetric
method based on weighing the filters both before and after aerosol
collection and by filter drying [10,11]. The output rate (ml/min)was
calculated using the following equation:
Output rate ml =minð Þ = inhalable mass mgð Þ =
Tobi concentration 60mg=mLð ÞX nebulization time minð Þ½ 
2.2.4. Aerodynamic particle size distribution of aerosols
Particle size distribution was measured using a laser
diffraction method (Mastersizer-X, Malvern, UK) [12]. The
aerosol was directed toward the laser beam. The dispersion code
was “polydisperse” and the optical presentation was “2QAA”.
Data inversion calculations were used to determine the Mass
Median Aerodynamic diameter (MMAD) and the fine particle
fraction (percentage of particles with a diameter of between 1
and 5 μm predicting the fraction of aerosol likely to be
deposited in the lungs [4,13]).
2.2.5. Study design
The 20 nebulizer systems were tested six times in random
order, with their corresponding interface, which was a
mouthpiece in 14 cases and a facemask in six cases (Cirrus®
1484, Hot Top Plus® 1464003, Kendall® 13962, Micromist®
41894, Misty-Neb ® 2033 G, Respineb® RN211). Either a
compressor or medical wall air at a flow rate of 8 L/min was
used for all the nebulizers.
2.3. In vivo study
Three healthy baboons weighing 9 kg to 12 kg were studied.
They were installed on a special chair under anesthesia
administered via an intra-muscular injection of xylazine
(1 mg/kg) and ketamine (5 mg/kg). They were then kept
awake while aerosol was administered through a face mask.
The face mask (Ref 93815028, Temsega, France), specifically
designed for baboons, was tight-fitting, and a system of one-
Table 1
In vitro nebulizer performances with Tobi (300 mg/5 mL) in adult ventilation model.
Nebulizer
reservoir
Interface Manufacturer Nebulizer
type
Air source MMAD
(μm)
Fine particle fraction
(%1–5 μm)
Inhalable
mass (mg)
Fine particle
mass (mg)
Time
(min)
Output rate
(ml/min)
Pressure
(bar)
Cirrus® 2505 (T piece) Intersurgical,
Wokingham, UK
Disposable Wall air 3.5±0.4 61±7 74±4 46±6 18±1 0.07±0.01 1.8±0.1
Cirrus® 1484 (face mask) Intersurgical,
Wokingham, UK
Disposable Wall air 4.4±1.6 55±16 67±5 37±13 20±2 0.06±0.01 1.9±0.1
Cirrus® 1485 (mouthpiece and T piece) Intersurgical,
Wokingham, UK
Disposable Wall air 4.0±1.2 62±13 67±2 41±9 18±2 0.06±0.01 1.8±0.1
Cirrus® 1485 (mouthpiece) Intersurgical,
Wokingham, UK
Disposable Pulmoaid
compressor
6.7±0.8 26±8 68±5 18±6 28±5 0.04±0.01 0.9±0.1
Hot Top Plus® 1464003 (face mask) Intersurgical,
Wokingham, UK
Disposable Wall air 3.3±0.1 76±4 50±9 38±6 10±1 0.08±0.02 2.0±0.2
Kendall® 13962 (face mask) Tyco Healthcare,
Germany
Disposable Wall air 5.6±1.3 39±11 53±4 20±5 8±1 0.11±0.02 1.8±0.1
Micro mist® 41894 (face mask) Hudson, Temecula,
USA
Disposable Wall air 5.7±2.3 43±12 62±4 27±8 10±1 0.10±0.02 1.8±0.1
Misty-Neb® 002033G (face mask) Cardinal Health,
Châteaubriant, France
Disposable Wall air 5.0±0.3 40±3 56±15 23±7 12±1 0.08±0.02 1.8±0.2
Misty-Neb® 002050G (mouth piece, tube,
Y piece, T piece, valve and filter)
Cardinal Health,
Châteaubriant, France
Disposable Wall air 0.7±0.1 6±5 12±3 1±1 12±1 0.02±0.01 1.7±0.2
Misty-Neb® 002035G (mouthpiece
and T piece)
Cardinal Health,
Châteaubriant, France
Disposable Wall air 4.8±0.2 49±3 66±3 32±3 12±1 0.10±0.01 1.8±0.1
Misty-Neb® 002035G (mouthpiece
and T piece)
Cardinal Health,
Châteaubriant, France
Disposable Pulmoaid
compressor
6.5±0.3 29±3 66±4 19±2 18±2 0.06±0.01 1.1±0.1
Respineb® RN211 (face mask) Teleflex, Le Faget,
France
Disposable Wall air 4.2±0.6 49±5 60±8 29±6 13±2 0.08±0.02 1.6±0.1
Sidestream® 12NEB400 (T piece and valve) Respironics, Bognor
Regis, UK
Disposable Wall air 0.9±0.2 29±23 27±4 8±7 9±1 0.03±0.01 1.5±0.1
Sidestream® 4452SU (mouthpiece) Respironics, Bognor
Regis, UK
Disposable Wall air 2.7±0.7 83±2 50±4 42±3 9±1 0.09±0.01 1.6±0.2
Sidestream® 4452SU (mouthpiece) Respironics, Bognor
Regis, UK
Disposable Portaneb
compressor
3.4±0.1 78±3 62±6 49±6 11±1 0.09±0.01 1.0±0.1
UP-DRAFT II
Optineb®
1734 (mouthpiece, T
piece and tube)
Teleflex, Research
Triangle Park, USA
Disposable Wall air 4.3±0.6 55±9 76±3 42±7 11±1 0.12±0.01 2.1±0.1
UP-DRAFT II
Optineb®
1734 (mouthpiece, T
piece and tube)
Teleflex, Research
Triangle Park, USA
Disposable Pulmoaid
compressor
5.0±0.2 45±3 83±4 38±3 21±3 0.07±0.01 1.0±0.1
Atomisor
NLU
mouthpiece Diffusion Technique
Française, France
One day Abox +
compressor
4.9±0.3 51±4 110±7 56±6 16±2 0.11±0.02 0.8±0.1
Pari LC Sprint mouthpiece Pari, Germany Six
months
Turboboy SX
compressor
3.9±0.2 62±4 134±9 84±8 13±3 0.17±0.03 1.5±0.1
Pari LC Plus mouthpiece Pari, Germany Six
months
Turboboy SX
compressor
3.4±0.2 64±8 116±10 74±6 14±1 0.14±0.01 1.7±0.1
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Fig. 1. Nebulizer image showing the same nebulizer reservoir (Mistyneb) connected with different interfaces resulting in different nebulizers system (A: Mistyneb
2050G, B: Mistyneb 2035G).
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baboon inhaled an aerosol produced by three different types of
nebulizer selected from the in vitro data.
PariLC+ with turbo boy compressor was used as the
reference nebulizer.
Mistyneb with the 2050G interface and Mistyneb with
2035G interface operating with wall air at 8 L/min were chosen
as examples of medium and low efficacy nebulizers
respectively.
The order of the nebulizers tested was randomized for each
baboon, resulting in nine inhalations.
99mTc-DTPA was used to label the tobramycin solution and
to perform the scintigraphic deposition study. It was prepared
from a commercially available kit (Pentacis®, CIS Bio
International, France) and mixed (74 MBq/0.2 mL) with Tobi
(300 mg/5 mL) in the nebulizer reservoir. The nebulizer charge
was controlled by counting the radioactivity in the syringe using
a gamma counter (Capintec®, France) before and after charging.
The nebulizer was then connected to the face mask and to an
expiratory filter to avoid air contamination. It was operated until
1 min after the aerosol began to sputter. Immediately after
aerosol delivery, the animals and the circuit components were
scanned using a gamma camera (Ecam, Siemens). A 120-s
posterior static view was acquired on a 128×128 matrix. The
amount of 99mTc-DTPA deposited in the lungs was determined
from the digitised images, taking into account attenuation
coefficients derived from lung perfusion imaging of each
baboon using pertechnetate-macroaggregated albumin. The
total lung surface was determined from the pertechnetate-
macroaggregated albumin scan. The amount of radioactivity
remaining in the nebulizer reservoir, face mask and filter was
determined with 120-s static acquisition imaging. The amount
deposited in the extrathoracic region (stomach + mouth) was
calculated by the activity balance method (difference between
the initial radioactivity loaded in the nebulizer and the activity
deposited in the lungs and circuit components). Corrections for
physical decay of 99mTc were made on all measurements.2.4. Data analysis
The fine particle mass, which is the amount of tobramycin
that is expected to deposit in the lungs, was calculated by
multiplying the inhalable mass by the fine particle fraction.
fine particle mass = Inhalable mass mgð Þ X fine particle fraction %ð Þ
The extrathoracic dose was defined as the amount of
tobramycin expected to deposit in the mouth or to be exhaled.
It was calculated by the difference between the inhalable mass
and the fine particle mass.
Results were presented as mean (SD) values.
A non-parametric test (Wilcoxon Mann Whitney) was used
to compare the data generated from the in vitro study, including
inhalable mass, nebulization time, operating pressure, MMAD,
fine particle fraction and output rate under different conditions,
using Statxact (Cytel Software Corporation, Version 3.0.2).
pb0.05 was considered statistically significant.
Comparison of nebulizer efficacy was based on the method
used by Standaert [13], which considers that nebulizers are
equivalent when fine particle mass is within 20% of the
reference at a 97.6% confidence level.
A Pearson correlation test was used to compare in vivo and
in vitro data in terms of fine particle mass, which corresponds to
the tobramycin mass deposited in the lungs in the in vivo study.
3. Results
3.1. In vitro
3.1.1. Comparison of nebulizer systems
The Pari LC Plus/Turboboy SX had a significantly higher
inhalable mass (pb0.002) and output rate (pb0.01) than all the
single-use disposable jet nebulizers (Table 1 and Fig. 2).
Comparison of the Pari LC plus and the Atomisor NLU in terms
of inhalable mass revealed no significant difference (p=0.4).
Fig. 2. Histogram of in vitro nebulizer performances in terms of fine particle mass predicting the amount of tobramycin deposited in the lungs, extrathoracic dose
predicting the amount of tobramycin and inhalable mass (fine particle mass + extrathoracic dose).
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disposable nebulizer performed as well as the Pari LC Plus/
Turboboy SX. The only nebulizer achieving the same
performance as the Pari LC Plus/Turboboy SX for fine particle
mass and nebulization time was the Pari LC Sprint/Turboboy
SX.
3.1.2. Influence of air source pressure
Compared to a wall air source operating at 8 L/min, a
compressor produced lower operating pressure with Cirrus
1485, Mistyneb 2035G, Sidestream 4452 U and Up Draft II
Optineb nebulizers (pb0.002). Air source had no influence on
inhalable mass for Cirrus 1485 and Mistyneb 2035G nebulizers
(pN0.84), but did have an influence on Sidestream 4452 U and
Up Draft II Optineb nebulizers (pb0.004). There was an
increase in nebulization time (pb0.004) and in MMAD
(pb0.04) for the four nebulizers when used with wall air,
resulting in decreased fine particle mass for Cirrus 1485 and
Mistyneb 2035G (pb0.02) and increased fine particle mass for
Sidestream 4452U (pb0.015). There was no influence of air
pressure on fine particle mass (p=0.36) for Up Draft II Optineb
but an increase in nebulization time (pb0.001).
3.1.3. Influence of the interface
The use of different interfaces with the Cirrus nebulizer
reservoir (producing different nebulizer systems: Cirrus 1485/
wall air, Cirrus 1484/wall air and Cirrus 2505/wall air) did not
have a significant impact on fine particle mass (pN0.25).
However, there was a significant influence of interface with
Mistyneb (Mistyneb 2035G/wall air vs. Mistyneb 2050G/wall
air) and Sidestream (Sidestream 4452U/wall air vs. Sidestream
12NEB400/wall air) reservoir nebulizers in terms of fine particle
mass (pb0.001). The 2050G interface used with the Mistynebreservoir produced a fine particle mass 32 times greater than that
obtained with the 2035G interface.
3.2. In vivo results
Deposition in the baboons' lungs differed significantly
between nebulizers (Fig. 2), with lung deposition about ten
times greater with Pari LC Plus/Turboboy SX than with
MistyNeb® 2050G operating with wall air (5.2 mg vs. 0.5 mg)
(Fig. 3). There was also a significant difference between the
MistyNeb® 2035G and the MistyNeb® 2050G in terms of
aerosol deposited in the lungs (2.1 mg vs. 0.5 mg), as shown in
Table 2. The ratio between the lungs and the extrathoracic
region reflects the aerosol amount of aerosol deposited in the
baboons' airways. There was a higher ratio for the Mistyneb
2050G than the Pari LC Plus/Turboboy SX and the Mistyneb
2035G, which can be explained by the low MMAD of the
Mistyneb 2050G (0.7 μm vs. 4.8 μm and 3.4 μm). Comparison
of fine particle mass and tobramycin mass deposited in the
baboons' lungs revealed a good correlation between in vivo and
in vitro data (r=0.91, n=9).
4. Discussion
This study investigated 20 nebulizer systems and air source
combinations which are commercially available on the French
market for the administration of tobramycin aerosol and which
are used both in CF centers and for home care.
Results obtained from our in vivo data are consistent with the
in vitro data (r=0.91, correlation test), with a higher mass of
tobramycin deposited in the lungs by the Pari LC Plus/
Turboboy SX than by the Mistyneb 2035G, and by the
Mistyneb 2035G than the Mistyneb 2050G. Most MMADs of
Fig. 3. Scintigraphy images obtained with baboons inhaling a tobramycin (Tobi, 300 mg/5 mL) aerosol nebulized by Pari LC+ operating with Turboboy SX
compressor (A), Mistyneb 2035G operating with wall air (8 L/min) and Mistyneb 2050G operating with wall air (8 L/min).
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and 5 μm and were not significantly different from the reference
nebulizer system (Pari LC Plus/Turboboy SX). However, the
Pari LC Plus/Turboboy SX had a significantly (pb0.001)
higher inhalable mass resulting in higher fine particle mass.
Based on Standaert's comparison method [13], neither of the
disposable jet nebulizers tested in this study performed as well
as the Pari LC Plus/Turboboy SX in terms of fine particle mass.
Only the Pari LC Sprint/Turboboy performed as well as the Pari
LC Plus/Turboboy SX reference nebulizer, and there was no
significant difference between these two nebulizers in terms of
duration of tobramycin nebulization.
There was no general correlation between air source and
nebulizer performance.
For some but not all nebulizers, compressor and wall air
produced similar fine particle mass, even though the pressure
was significantly different (pb0.001). These results confirm the
need to match the nebulizer/air source combination carefully to
achieve optimum performance [14].
Many nebulizer systems use the same reservoir and differ in
interface. Changing the interface but keeping the same reservoir
can result in different fine particle fraction, inhalable mass and
fine particle mass. This was the case for the Mistyneb® and
Sidestream® nebulizers when powered with wall air (Table 1).
The difference in terms of fine particle mass attained a factor ofTable 2
In vivo results for Tobi aerosol inhalation with baboons. Results are expressed in
term of tobramycin mass deposited into the lungs and in term of ratio between
lung and extrathoracic aerosol deposition.
Nebulizer Pari LC+/
Turboboy SX
Mistyneb 2035G/
Wall air
Mistyneb 2050G/
Wall air
Lung
(mg)
Lung/
extrathoracic
Lung
(mg)
Lung/
extrathoracic
Lung
(mg)
Lung/
extrathoracic
Baboon 1 8.0 0.4 1.9 0.2 0.5 1.0
Baboon 2 5.2 0.5 2.1 0.3 0.4 1.9
Baboon 3 4.2 0.5 3.8 0.7 0.7 1.232 for the Mistyneb 2050G when compared with the Mistyneb
2035G. These large differences between nebulizers in terms of
performance can be explained by residual mass remaining in the
nebulizer at the end of nebulization and aerosol leakage during
expiratory phases. The Pari LC+ nebulizer is a breath-enhanced
jet nebulizer producing less aerosol leakage than standard
continuous jet nebulizers such as Mistyneb. Furthermore, the
residual mass is determined by the nebulizer geometry
including reservoir and interface. Mistyneb 2050G differs
from the 2035G in its interface which contains tubing and a
valve, on which some aerosol droplets might impact, which
could also explain the difference in terms of particle size
(MMAD 0.7 μm vs. 5.0 μm).
These high differences obtained from in vitro measurements
were confirmed by the scintigraphic study comparing Mistyneb
2050G and Mistyneb 2035G but with a lower range of
difference (a factor of 4 instead of a factor of 32). This
difference can be explained by the macaque model, which is
consistent with a child's breathing pattern and results in
different ventilation parameters and anatomy of airways than
the adult pattern which was modeled in the in vitro study, and
also by the definition of fine particle fraction which does not
take into account particle size less than 1 μm [2].
In conclusion, none of the single-use disposable nebulizers
tested in this study can be considered as a suitable alternative to
the Pari LC Plus® for administering tobramycin aerosols.
There was no general relationship between the compressed
air source (compressor or wall air) and performance of the
nebulizer system. The performance of some nebulizers did not
change when using different air sources, while the performance
of others did.
This study highlights the influence of the interface on the
nebulizer reservoir. This parameter can have a significant
impact on treatment efficacy.
The choice of a nebulizer/interface/air source combination
must be made carefully, as any change in the air source or the
interface of the nebulizer can have a dramatic impact on the
efficacy of the aerosolized tobramycin treatment.
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